Riskpilot← Back to searchSign inGet full accessSACRA Therapeutics AB
ABActiveOrg 5593381246LundResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20210 employees
Revenue 2024
SEK 0
EBITDA margin
—
+69% vs 2023
Equity ratio
99.9%
Financial strength
Net profit 2024
SEK -374K
+5% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -20K | +69% |
| Net profit | SEK -374K | +5% |
| Total assets | SEK 3,4M | -3% |
| Equity | SEK 3,4M | -1% |
| Employees | 0 | — |
Legal name
SACRA Therapeutics AB
Org number
5593381246
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1 oktober 2021
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna
Company purpose
Bolaget skall bedriva forskning, utveckling och kommersialisering av läkemedel.
Address
Lund
Email
annhelen.forsling@redglead.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Staff expenses | — | — | — |
| EBITDA | −165 | −64 | −20 |
| Depreciation & amort. | −0 | −0 | −0 |
| EBIT | −165 | −64 | −20 |
| Net financials | −319 | −332 | −354 |
| Profit before tax | −484 | −395 | −374 |
| Tax | −0 | −0 | −0 |
| Net profit | −484 | −395 | −374 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 3 656 | 3 544 | 3 440 |
| Equity | 51 | 3 456 | 3 436 |
| Long-term debt | 3 469 | 0 | 0 |
| Short-term debt | 137 | 87 | 4 |
| Total debt | 3 606 | 87 | 4 |
EBITDA margin
-2000000.0%
This company
15.8%
Market median
-12658328% vs market
20222024
Equity ratio
99.9%
This company
38.2%
Market median
+162% vs market
20222024
Return on equity
-10.9%
This company
18.4%
Market median
-159% vs market
20222024
Net profit margin
-37400000.0%
This company
8.1%
Market median
-461728495% vs market
20222024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20222024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20222024
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Chairman | 2025 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
| Former (5) | ||
| Board of Directors | 2021 – 2022 | |
| Chairman | 2022 – 2025 | |
| Deputy Board Member | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SACRA Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lina Anna Elisabeth Nordström | Board of Directors | 0 companies |
| Cristian Bellodi | Chairman | 0 companies |
| Sowndarya Muthukumar | Board of Directors | 0 companies |
| Martina Kvist Reimer | Board of Directors | 0 companies |
| Ana Bosch Campos | Chairman | 0 companies |
| Lars Hugo Viking Rillner | Deputy Board Member | 0 companies |
| Petra Maria Nilsson Andersson | Deputy Board Member | 0 companies |
| Henrik Daniel Karlsson | Deputy Board Member | 0 companies |
| Lars Johan Evenäs | Deputy Board Member | 0 companies |